Abstract

We examined the overall survival rates of a national cohort to determine optimal treatments and prognostic factors for patients with metachronous second primary head and neck squamous cell carcinomas (mspHNSCCs) at different stages and sites. We analyzed data of mspHNSCC patients collected from the Taiwan Cancer Registry database. The patients were categorized into four groups based on the treatment modality: Group 1 (control arm; chemotherapy [CT] alone), Group 2 (reirradiation [re-RT] alone with intensity-modulated radiotherapy [IMRT]), Group 3 (concurrent chemoradiotherapy alone [irradiation with IMRT]), and Group 4 (salvage surgery with or without RT or CT). We enrolled 1741 mspHNSCC patients without distant metastasis. Multivariate Cox regression analyses revealed that Charlson comorbidity index (CCI) ≥6, stage of second HNSCC, stage of first HNSCC, and duration from first primary HNSCC of <3 years were significant poor independent prognostic risk factors for overall survival. After adjustment, adjusted hazard ratios and 95% confidence intervals for the overall all-cause mortality risk at mspHNSCC clinical stages III and IV were 0.72 (0.40–1.82), 0.52 (0.35–0.75), and 0.32 (0.22–0.45) in Groups 2, 3, and 4, respectively. A Cox regression analysis indicated that a re-RT dose of ≥6000 cGy was an independent protective prognostic factor for treatment modalities. CCI ≥ 6, stage of second HNSCC, stage of first HNSCC, and duration from first primary HNSCC of <3 years were significant poor independent prognostic risk factors for overall survival. A re-RT dose of ≥6000 cGy may be necessary for mspHNSCCs.

Original languageEnglish
Pages (from-to)142-153
Number of pages12
JournalCancer Medicine
Volume6
Issue number1
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Survival
Intensity-Modulated Radiotherapy
Regression Analysis
Drug Therapy
Chemoradiotherapy
Taiwan
Registries
Comorbidity
Therapeutics
Survival Rate
Carcinoma, squamous cell of head and neck
Databases
Confidence Intervals
Neoplasm Metastasis
Control Groups
Mortality
Re-Irradiation
Neoplasms

Keywords

  • Head and neck cancer
  • incidence
  • metachronous second primary
  • prognostic factors
  • survival
  • treatment outcomes

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma. / Chen, Jin-Hua; Yen, Yu-Chun; Chen, Tsung Ming; Yuan, Kevin Sheng Po; Lee, Fei-Peng; Lin, Kuan Chou; Lai, Ming-Tang; Wu, Chia-Che; Chang, Chia Lun; Wu, Szu-Yuan.

In: Cancer Medicine, Vol. 6, No. 1, 01.01.2017, p. 142-153.

Research output: Contribution to journalArticle

@article{8a9894378a894f1c8e66b6aa09f164cf,
title = "Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma",
abstract = "We examined the overall survival rates of a national cohort to determine optimal treatments and prognostic factors for patients with metachronous second primary head and neck squamous cell carcinomas (mspHNSCCs) at different stages and sites. We analyzed data of mspHNSCC patients collected from the Taiwan Cancer Registry database. The patients were categorized into four groups based on the treatment modality: Group 1 (control arm; chemotherapy [CT] alone), Group 2 (reirradiation [re-RT] alone with intensity-modulated radiotherapy [IMRT]), Group 3 (concurrent chemoradiotherapy alone [irradiation with IMRT]), and Group 4 (salvage surgery with or without RT or CT). We enrolled 1741 mspHNSCC patients without distant metastasis. Multivariate Cox regression analyses revealed that Charlson comorbidity index (CCI) ≥6, stage of second HNSCC, stage of first HNSCC, and duration from first primary HNSCC of <3 years were significant poor independent prognostic risk factors for overall survival. After adjustment, adjusted hazard ratios and 95{\%} confidence intervals for the overall all-cause mortality risk at mspHNSCC clinical stages III and IV were 0.72 (0.40–1.82), 0.52 (0.35–0.75), and 0.32 (0.22–0.45) in Groups 2, 3, and 4, respectively. A Cox regression analysis indicated that a re-RT dose of ≥6000 cGy was an independent protective prognostic factor for treatment modalities. CCI ≥ 6, stage of second HNSCC, stage of first HNSCC, and duration from first primary HNSCC of <3 years were significant poor independent prognostic risk factors for overall survival. A re-RT dose of ≥6000 cGy may be necessary for mspHNSCCs.",
keywords = "Head and neck cancer, incidence, metachronous second primary, prognostic factors, survival, treatment outcomes",
author = "Jin-Hua Chen and Yu-Chun Yen and Chen, {Tsung Ming} and Yuan, {Kevin Sheng Po} and Fei-Peng Lee and Lin, {Kuan Chou} and Ming-Tang Lai and Chia-Che Wu and Chang, {Chia Lun} and Szu-Yuan Wu",
year = "2017",
month = "1",
day = "1",
doi = "10.1002/cam4.976",
language = "English",
volume = "6",
pages = "142--153",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma

AU - Chen, Jin-Hua

AU - Yen, Yu-Chun

AU - Chen, Tsung Ming

AU - Yuan, Kevin Sheng Po

AU - Lee, Fei-Peng

AU - Lin, Kuan Chou

AU - Lai, Ming-Tang

AU - Wu, Chia-Che

AU - Chang, Chia Lun

AU - Wu, Szu-Yuan

PY - 2017/1/1

Y1 - 2017/1/1

N2 - We examined the overall survival rates of a national cohort to determine optimal treatments and prognostic factors for patients with metachronous second primary head and neck squamous cell carcinomas (mspHNSCCs) at different stages and sites. We analyzed data of mspHNSCC patients collected from the Taiwan Cancer Registry database. The patients were categorized into four groups based on the treatment modality: Group 1 (control arm; chemotherapy [CT] alone), Group 2 (reirradiation [re-RT] alone with intensity-modulated radiotherapy [IMRT]), Group 3 (concurrent chemoradiotherapy alone [irradiation with IMRT]), and Group 4 (salvage surgery with or without RT or CT). We enrolled 1741 mspHNSCC patients without distant metastasis. Multivariate Cox regression analyses revealed that Charlson comorbidity index (CCI) ≥6, stage of second HNSCC, stage of first HNSCC, and duration from first primary HNSCC of <3 years were significant poor independent prognostic risk factors for overall survival. After adjustment, adjusted hazard ratios and 95% confidence intervals for the overall all-cause mortality risk at mspHNSCC clinical stages III and IV were 0.72 (0.40–1.82), 0.52 (0.35–0.75), and 0.32 (0.22–0.45) in Groups 2, 3, and 4, respectively. A Cox regression analysis indicated that a re-RT dose of ≥6000 cGy was an independent protective prognostic factor for treatment modalities. CCI ≥ 6, stage of second HNSCC, stage of first HNSCC, and duration from first primary HNSCC of <3 years were significant poor independent prognostic risk factors for overall survival. A re-RT dose of ≥6000 cGy may be necessary for mspHNSCCs.

AB - We examined the overall survival rates of a national cohort to determine optimal treatments and prognostic factors for patients with metachronous second primary head and neck squamous cell carcinomas (mspHNSCCs) at different stages and sites. We analyzed data of mspHNSCC patients collected from the Taiwan Cancer Registry database. The patients were categorized into four groups based on the treatment modality: Group 1 (control arm; chemotherapy [CT] alone), Group 2 (reirradiation [re-RT] alone with intensity-modulated radiotherapy [IMRT]), Group 3 (concurrent chemoradiotherapy alone [irradiation with IMRT]), and Group 4 (salvage surgery with or without RT or CT). We enrolled 1741 mspHNSCC patients without distant metastasis. Multivariate Cox regression analyses revealed that Charlson comorbidity index (CCI) ≥6, stage of second HNSCC, stage of first HNSCC, and duration from first primary HNSCC of <3 years were significant poor independent prognostic risk factors for overall survival. After adjustment, adjusted hazard ratios and 95% confidence intervals for the overall all-cause mortality risk at mspHNSCC clinical stages III and IV were 0.72 (0.40–1.82), 0.52 (0.35–0.75), and 0.32 (0.22–0.45) in Groups 2, 3, and 4, respectively. A Cox regression analysis indicated that a re-RT dose of ≥6000 cGy was an independent protective prognostic factor for treatment modalities. CCI ≥ 6, stage of second HNSCC, stage of first HNSCC, and duration from first primary HNSCC of <3 years were significant poor independent prognostic risk factors for overall survival. A re-RT dose of ≥6000 cGy may be necessary for mspHNSCCs.

KW - Head and neck cancer

KW - incidence

KW - metachronous second primary

KW - prognostic factors

KW - survival

KW - treatment outcomes

UR - http://www.scopus.com/inward/record.url?scp=85010634319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010634319&partnerID=8YFLogxK

U2 - 10.1002/cam4.976

DO - 10.1002/cam4.976

M3 - Article

C2 - 27987269

AN - SCOPUS:85010634319

VL - 6

SP - 142

EP - 153

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 1

ER -